BioSpace News Archive

Today, MyHealthTeams and EMD Serono, through their MS-LINK initiative, announced the launch of the Treatment and Adherence Resource Center within MyMSTeam, the social network for people living with multiple sclerosis (MS).

Dahua Technology, a world-leading, video-centric provider of smart IoT solutions, has announced the launch of SafetyTemp (DHI-ASI7213X-T1), a thermal temperature monitoring station.

Full results from the positive Phase III ETHOS trial showed AstraZeneca’s triple-combination therapy PT010 (budesonide/glycopyrronium/formoterol fumarate) demonstrated a statistically significant reduction in the rate of moderate or severe exacerbations compared with two dual-combination therapies in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer (OEM) ceramics company focused on silicon nitride and its applications, today announced positive testing results demonstrating the anti-viral properties of its silicon nitride which may be useful in the reduction of the spread of COVID-19.

BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), today announced that it intends to satisfy its obligation to pay $26,177.21 in interest to the holders of its 7.5% unsecured debentures issued December 23, 2019

U.S. Secretary of Agriculture Sonny Perdue and FDA Commissioner Stephen M. Hahn, M.D., issued the following statement regarding food export restrictions pertaining to COVID-19

Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologic therapies, today announced that it intends to offer and sell, subject to market and other conditions, $40 million of its common stock in an underwritten public offering.

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that the underwriters of its recently closed underwritten offering of 12,633,039 shares of its common stock

Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced that the Company plans to release its fourth quarter and fiscal year-end 2020 financial results on Tuesday, July 21, 2020 after the close of trading.

Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today reported its financial and operational results for the year ended March 31, 2020.